Logo

Cardiff Oncology, Inc.

CRDF

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials… read more

Healthcare

Biotechnology

22 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.86

Price

+0.52%

$0.01

Market Cap

$56.136m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-8970.0%

EBITDA Margin

-9381.7%

Net Profit Margin

-9043.3%

Free Cash Flow Margin

-8970.0%

EBITDA Margin

-9381.7%

Net Profit Margin

-9043.3%

Free Cash Flow Margin
Revenue

$525k

-26.6%

1y CAGR

+13.2%

3y CAGR

+11.8%

5y CAGR
Earnings

-$44.762m

-11.0%

1y CAGR

-9.2%

3y CAGR

-16.1%

5y CAGR
EPS

-$0.67

+4.2%

1y CAGR

-0.8%

3y CAGR

-6.1%

5y CAGR
Book Value

$34.709m

$49.172m

Assets

$14.463m

Liabilities

$646k

Debt
Debt to Assets

1.3%

-

Debt to EBITDA
Free Cash Flow

-$37.461m

-11.9%

1y CAGR

-7.5%

3y CAGR

-18.0%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases